Hong Kong firm invests in Jena-based Oncgnostics GmbH

12-Sep-2023 - The Hong Kong-based company Grande Bio-tech Co. Ltd. is making a seven-digit Euros investment in the Jena-based diagnostic company Oncgnostics GmbH. Oncgnostics has developed the cancer diagnostic Gyntect for the reliable detection of cervical cancer. Since 2022, this test has also been ...

Cancer screening from home?

Detection with independently taken samples can work

12-Aug-2021 - A large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much less frequent since the onset of the corona pandemic. A study by Hannover Medical School and the ...

oncgnostics cooperates with the Medical University of Graz

Study on Head-and-Neck tumors aims to demonstrate that a diagnostic method can reliably and early detect malignant tumors using non-invasive saliva samples

23-Apr-2021 - The biotechnology company oncgnostics GmbH is researching a method for diagnosing Head-and-Neck tumors together with the clinical department for general ENT at the Medical University of Graz as part of the “OroCa-Graz” study. 550,000 people worldwide develop carcinomas of this type every year. As ...

oncgnostics starts international sales partnership with EUROIMMUN

16-Apr-2021 - Biotechnology company oncgnostics GmbH is announcing a collaboration with the international diagnostics group EUROIMMUN, a PerkinElmer company. As part of the cooperation, EUROIMMUN will sell the cervical cancer test from oncgnostics GmbH, Gyn-Tect, in the European countries of Portugal, Italy, ...

New financing round at oncgnostics GmbH close

18-Oct-2018 - The life sciences company oncgnostics GmbH was able to double its investment of 750,000 euros following the very rapid and successful completion of its second crowd investing campaign on Seedmatch. A group of private investors invests together with beteiligungsmanagement thüringen GmbH (bm|t) in ...

Oncgnostics GmbH obtains seed funding for financing preclinical and clinical trials

High-Tech Gründerfonds and STIFT invest into molecular cancer diagnostics from Jena

19-Apr-2012 - Chemical alterations of the genetic information specifically occuring during carcinogenesis provide the basis for the innovative diagnostic tests that are developed by the newly established oncgnostics GmbH in Jena. These tests allow not only for an earlier, but also a more accurate detection of ...